
Encompass Health (EHC) Stock Forecast & Price Target
Encompass Health (EHC) Analyst Ratings
Bulls say
Encompass Health is positioned to compound growth through an under-supplied inpatient rehabilitation network, with 3Q26 revenue of $1.61B and adjusted EBITDA of $346.6M beating expectations while margins expanded to 21.5%. Its outlook is supported by strong volume trends, higher-acuity mix gains in neuro, stroke, brain injury and major trauma, and meaningful VA demand, which helped lift FY26 guidance to $6.45B-$6.50B of revenue and $1.395B-$1.415B of adjusted EBITDA. The company also has a disciplined growth engine with 145-190 bed additions in 2026, net leverage of 1.8x, and robust free cash flow that supports further investment, buybacks, and dividend growth.
Bears say
Encompass Health is exposed to persistent margin pressure because staffing costs and turnover remain elevated while reimbursement generally lags, leaving profitability vulnerable even as patient volume has recently recovered. Its outlook is further weakened by regulatory and payer risks, since CMS has generally issued more onerous reimbursement and regulatory provisions and could reduce IRF rates while Medicare Advantage plans may pressure admissions. The company also faces execution risk from de novo facilities and bed additions that may ramp slower than expected, plus a tight labor market for therapists, nurses, and other professionals with wage inflation outpacing price growth.
This aggregate rating is based on analysts' research of Encompass Health and is not a guaranteed prediction by Public.com or investment advice.
Encompass Health (EHC) Analyst Forecast & Price Prediction
Start investing in Encompass Health (EHC)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Encompass Health (EHC) Forecast
Encompass Health (EHC) Analyst Forecast & Price Prediction
Start investing in Encompass Health (EHC)
Order type
Buy in
Order amount
Est. shares
0 shares